← All trials
NCT05786469
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 2, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Mar 27, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mario Negri InstituteLead sponsor
- Vifor Inc.Collaborator
- Mario Negri InstituteStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.